Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
WM Brückl, M Reck, F Griesinger… - Therapeutic …, 2021 - journals.sagepub.com
Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
[PDF][PDF] Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice 2
WM Brückl, JH Ficker, M Reck, F Griesinger, H Schäfer… - scholar.archive.org
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in
routine clinical practice Page 1 1 Afatinib as first-line treatment in patients with EGFR-mutated …
routine clinical practice Page 1 1 Afatinib as first-line treatment in patients with EGFR-mutated …
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.
WM Brückl, M Reck, F Griesinger, H Schäfer… - … Advances in Medical …, 2021 - europepmc.org
Background Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.
WM Brückl, M Reck, F Griesinger… - Therapeutic …, 2021 - search.ebscohost.com
Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
[PDF][PDF] Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice 2
WM Brückl, JH Ficker, M Reck, F Griesinger, H Schäfer… - sage.figshare.com
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in
routine clinical practice Page 1 1 Afatinib as first-line treatment in patients with EGFR-mutated …
routine clinical practice Page 1 1 Afatinib as first-line treatment in patients with EGFR-mutated …
[引用][C] Afatinib as first-line treatment in patients with
W Brückl, M Reck, F Griesinger, H Schäfer… - THERAPEUTIC …, 2021 - pure.pmu.ac.at
Afatinib as first-line treatment in patients with — PMU Research Portal Skip to main navigation
Skip to search Skip to main content PMU Research Portal Home PMU Research Portal Logo …
Skip to search Skip to main content PMU Research Portal Home PMU Research Portal Logo …
[HTML][HTML] Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
WM Brückl, M Reck, F Griesinger… - … Advances in Medical …, 2021 - ncbi.nlm.nih.gov
Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
WM Brückl, M Reck, F Griesinger… - Therapeutic …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
[引用][C] Afatinib as first-line treatment in patients with
W Brückl, M Reck, F Griesinger, H Schäfer… - THERAPEUTIC …, 2021 - pure.pmu.ac.at
Afatinib as first-line treatment in patients with — PMU Forschungsportal Zur
Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln PMU …
Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln PMU …
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.
WM Brückl, M Reck, F Griesinger… - Therapeutic …, 2021 - search.ebscohost.com
Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …